Cargando…
PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells
Previous studies showed that type II cGMP-dependent protein kinase G (PKG II) could inhibit the activation of epidermal growth factor receptor (EGFR). Both c-Met and EGFR belong to family of receptor tyrosine kinases (RTKs) and have high molecular analogy. However, the effect of PKG II on c-Met acti...
Autores principales: | Wu, Yan, Yao, Xiaoyuan, Zhu, Miaolin, Qian, Hai, Jiang, Lu, Lan, Ting, Wu, Min, Pang, Ji, Chen, Yongchang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085148/ https://www.ncbi.nlm.nih.gov/pubmed/27147579 http://dx.doi.org/10.18632/oncotarget.9074 |
Ejemplares similares
-
The constitutively active PKG II mutant effectively inhibits gastric cancer development via a blockade of EGF/EGFR-associated signalling cascades
por: Wu, Yan, et al.
Publicado: (2018) -
Protein Kinases Type II (PKG II) Combined with L-Arginine Significantly Ameliorated Xenograft Tumor Development: Is L-Arginine a Potential Alternative in PKG II Activation?
por: Wu, Yan, et al.
Publicado: (2018) -
PKG II Inhibits EGF/EGFR-Induced Migration of Gastric Cancer Cells
por: Jiang, Lu, et al.
Publicado: (2013) -
Role of PKG II in osteoblast mechanotransduction
por: Rangaswami, Hema, et al.
Publicado: (2009) -
MET transcriptional regulator/serine peptidase inhibitor kunitz type 1 panel operating through HGF/c‐MET axis as a prognostic signature in pan‐cancer
por: Xiang, Yi, et al.
Publicado: (2021)